Acquisition of Rokshaw, a leading UK Specials manufacturer

Immediate access to UK medical cannabis market 9 April 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce completion of the acquisition of the entire issued share capital of Rokshaw Limited (“Rokshaw”), a leading UK MHRA approved Specials manufacturer, by EMMAC’s UK subsidiary, EMMAC UK Limited. The acquisition […]

Medalchemy, EMMAC’s Spanish GMP certified laboratory, secures approval to import medical cannabis for scientific research

Research

19 March 2019, London: EMMAC, the European independent medical cannabis company, is pleased to announce that Medalchemy, EMMAC’s fully-licensed GMP certified laboratory in Alicante, Spain, has secured approval from the Spanish Health Authorities AEMPS to import medical cannabis for scientific research. This landmark announcement places Medalchemy at the forefront of medical cannabis research in Spain, […]

£11 million raised via successful Private Placing

‘Oversubscribed placing with institutional investment from across Europe, North America, Asia and Australia’ 8 March 2019, London. EMMAC Life Sciences Limited, the European independent medical cannabis company, is pleased to announce that the Company has raised £11 million via a successful private placing (the ‘Placing’) providing the Company with a post money valuation of £77 […]

EMMAC Announces Turnkey GMP Facility in Malta to be Group Import and Distribution Hub

EMMAC granted a Letter of Intent under terms of the Production of Cannabis for Medicinal Use Act 2018 EMMAC, the European independent medical cannabis company, is pleased to announce that Malta Enterprise, the Maltese government’s exclusive agency focused on attracting inward investment and supporting enterprise in Malta, has granted EMMAC a Letter of Intent under […]

Announcing the acquisition of leading Swiss wellness CBD company Blossom

Reserved wood

Emmac Life Sciences (“EMMAC” or the “Company”) is pleased to announce the acquisition of Blossom, a market-leading Swiss wellness CBD company. The acquisition provides EMMAC with a revenue-making portfolio of premium wellness CBD products and an established brand leadership position. Founded in 2017, Blossom has quickly become a reference in the Swiss market and is […]

Board and Leadership Appointments

Dr Barbara Pacchetti as Chief Scientific Officer and Dr Mikael Sodergren as Research Director  Recognised scientific pioneers to drive research and innovation to shape the global future of medicinal cannabis EMMAC, the European independent medical cannabis company, is pleased to announce the appointment of two internationally acclaimed scientific leaders to its Board and Leadership team. […]

Research collaboration with Imperial College London

Press Release

A pre-clinical and clinical research programme to investigate cannabis-based medicinal products aimed to directly benefit patients. EMMAC, the European independent medical cannabis company, is pleased to announce a research collaboration with Imperial College London to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry. The […]